Shares of Moderna (MRNA) rose 8.7% on Mar 11, after a government website posted details of the initiation of a phase II/III study on mRNA-4157/V940, its investigational individualized neoantigen therapy (INT), in patients with cutaneous squamous cell carcinoma (CSCC), a form of skin cancer. The therapy is being developed in collaboration with Merck (MRK) .The phase II/III study (called INTerpath-007) will evaluate the safety and efficacy of mRNA-4157, combined with Merck’s blockbuster immuno-oncology drug K ...

Moderna (MRNA) shares soared 8.7% in the last trading session to close at $111.98. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17.9% gain over the past four weeks.Share price rose after a government website posted details of initiation of a phase II/III study on mRNA-4157/V940, Moderna’s investigational individualized neoantigen therapy (INT), in patients with cutaneous squamous cell carcinoma (CSCC), a form of skin cancer. T ...

Key TakeawaysThe S&P 500 slipped 0.1% on Monday, March 11, 2024, ahead of inflation data that could affect rate-cut expectations.Shares of EQT fell after the natural gas producer announced plans to purchase pipeline provider Equitrans Midstream.Moderna shares gained amid reports that it will launch a study of its experimental cancer vaccine to treat patients with a form of skin cancer. Major U.S. equities indexes were mixed to open the trading week as stocks fluttered ahead of Tuesday's Consumer Price Infla ...

As an investor, you never really know how your investments will play out. Some companies that have been in long-term decline can suddenly become turnaround stocks and rise again, surprising everyone. While most companies that are undertaking a turnaround strategy fail, some manage to get their act together and regain their competitive edge. This isn’t easy and usually takes a long time to accomplish, but it can be done. And when it happens, shareholders are rewarded with big gains. In the just-completed ear ...

The past four years have been a roller-coaster ride for Moderna (MRNA 3.06%). The mRNA-focused vaccine maker rose to prominence following a successful attempt at developing a coronavirus vaccine.However, the stock fell out of favor once sales of the company's only product on the market started moving in the wrong direction. Moderna's shares are down by 30% in the past year, but their total return over the past four years is 230%, and there remain good reasons to invest in the company. 1. Gaining market shar ...

Regarding Moderna (MRNA 2.32%) stock, RBC Capital analyst Luca Issi is bullish. Per his price target of $125 that he reiterated on Feb. 23, the biotech's shares could rise by 30% to reach $125. There are a few upcoming developments that could stimulate the stock to grow in the way that Issi predicts.Management expects its respiratory syncytial virus (RSV) vaccine will pick up a few regulatory approvals in the first half of the year, paving the way for worldwide launches, with sales revenue to follow. Separa ...

Moderna, Inc. (MRNA) reported earnings of 55 cents per share in the fourth quarter of 2023, beating the Zacks Consensus Estimate of a loss of 78 cents. Earnings declined 85% in the quarter. The year-over-year decline in the bottom line was due to lower product sales during the quarter.Revenues in the quarter were $2.81 billion, beating the Zacks Consensus Estimate of $2.55 billion. Total revenues declined 45% year over year due to lower COVID-19 vaccine sales during the quarter.Moderna’s shares were up 6.1% ...

Shares of Moderna (MRNA 10.02%) were jumping 9.5% higher as of 11:09 a.m. ET on Thursday after rising as much as 10% earlier in the day. The gain came after the biotech company announced its fourth-quarter and fiscal year 2023 results.The big news in Moderna's Q4 update was a surprise profit of $217 million, or $0.53 per share, based on generally accepted accounting principles (GAAP). The average analysts' estimate was for a Q4 loss of $0.90 per share.Moderna also reported Q4 revenue of $2.8 billion, down f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38753 Moderna, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organi ...

Moderna (MRNA) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of a loss of $0.78 per share. This compares to earnings of $3.61 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 170.51%. A quarter ago, it was expected that this biotechnology company would post a loss of $2.01 per share when it actually produced a loss of $1.39, delivering a surprise of 30.85%.Over the last four quarters, ...